Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 12/20 | 0.45 |
| ▸ | PARP1 | P09874 | 3/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.39 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4517529 | 0.91 | AKR1C3 (0.43) | HSP90AA1MAP4K4CSNK1G2CLK4MKNK2 | |
| SCHEMBL4508039 | 0.91 | MAP4K4 (0.47) | HSP90AA1MAP4K4CSNK1G2CLK4MKNK2 | |
| SCHEMBL4527360 | 0.88 | NR2F2 (0.40) | HSP90AA1MAP4K4CSNK1G2CLK4MKNK2 | |
| SCHEMBL4526637 | 0.86 | MAP4K4 (0.40) | HSP90AA1MAP4K4CSNK1G2CLK4MKNK2 | |
| SCHEMBL4508379 | 0.84 | MAP4K4 (0.38) | HSP90AA1MAP4K4CSNK1G2CLK4MKNK2 | |
| SCHEMBL4508381 | 0.84 | MAP4K4 (0.38) | HSP90AA1MAP4K4CSNK1G2CLK4MKNK2 | |
| SCHEMBL4521817 | 0.84 | NR2F2 (0.40) | HSP90AA1MAP4K4CSNK1G2CLK4MKNK2 | |
| Oxalic Acid SCHEMBL4521269 | 0.82 | AKR1C3 (0.48) | HSP90AA1MAP4K4CSNK1G2CLK4MKNK2 | |
| SCHEMBL4529985 | 0.82 | BIRC5 (0.42) | MAP4K4CSNK1G2CLK4MKNK2MAP4K5 | |
| SCHEMBL4527597 | 0.82 | ALDH1A1 (0.49) | MAP4K4CSNK1G2CLK4MKNK2MAP4K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1736471-B1 | 3-(DIHYDRO(TETRAHYDRO)ISOQUINOLIN-1-YL)QUINOLINES | MITSUI CHEMICALS AGRO INC (JP) | 2014-01-08 | — | — | EP | disclosed |
| US-7632783-B2 | fungicides, pesticides for protecting rice crop, tomatoes, cucumbers and green beans; 3-(5-fluoro-3,3-dimethyl-3,4-dihydroisoquinolin-1-yl)quinoline | MITSUI CHEMICALS AGRO, INC. (JP) | 2009-12-15 | — | — | US | disclosed |
| CN-100556904-C | 3- (dihydro (tetrahydro) isoquinolin-1-yl) quinoline compounds | SANKYO AGRO CO LTD (JP) | 2009-11-04 | — | — | CN | disclosed |
| US-20080275242-A1 | 3-(Dihydro(Tetrahydro)Isoquinolin-1-Yl)Quinoline Compound | MITSUI CHEMICALS CROP & LIFE SOLUTIONS, INC. (JP) | 2008-11-06 | — | — | US | disclosed |
| CN-1910172-A | 3- (dihydro (tetrahydro) isoquinolin-1-yl) quinoline compounds | SANKYO AGRO CO LTD (JP) | 2007-02-07 | — | — | CN | disclosed |
| EP-1736471-A1 | 3-(DIHYDRO(TETRAHYDRO)ISOQUINOLIN-1-YL)QUINOLINES | Sankyo Agro Company, Limited (JP) | 2006-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275242-A1 | 3-(Dihydro(Tetrahydro)Isoquinolin-1-Yl)Quinoline Compound | QTRT1, RABL3, RECQL | HSP90AA1 2066/4885PARP1 1368/4885MAP4K4 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.